Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma
- PMID: 32051207
- DOI: 10.1136/gutjnl-2020-320604
Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma
Keywords: cancer; hepatobiliary cancer; hepatocellular carcinoma; immunotherapy.
Conflict of interest statement
Competing interests: ENDT has served as a paid consultant for AstraZeneca, Bayer, BMS, EISAI, Eli Lilly & Co, Pfizer, IPSEN and Roche. He has received reimbursement of meeting attendance fees and travel expenses from Arqule, BMS, Bayer, Celsion and Roche, and lecture honoraria from BMS and Falk. He has received third-party funding for scientific research from Arqule, AstraZeneca, BMS, Bayer, Eli Lilly and Roche. DR has received reimbursement of meeting attendance fees and travel expenses from Celsion and IPSEN.
Comment on
-
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Gut. 2018. PMID: 29150490 Free PMC article.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical